Format

Send to

Choose Destination
Blood Adv. 2019 Dec 10;3(23):4131-4135. doi: 10.1182/bloodadvances.2019000898.

Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib.

Author information

1
Division of Oncology, Department of Medicine.
2
Division of Hematology, Department of Medicine, and.
3
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO.

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center